NantHealth Story

NH -- USA Stock

USD 4.07 0.33 8.82%

Macroaxis Story

Whilst many millenniums are getting more into healthcare space, it makes sense to concentrate on NantHealth. We will evaluate why we are still confident in anticipation of a recovery. Is the firm valuation justified? Here I will cover 2020 perspective on the current valuation of NantHealth to give you a better outlook on taking a possible position in this stock.

Published over a month ago

View all stories for NantHealth | View All Stories

Is NantHealth (NASDAQ:NH) ready for a correction?

This firm reports 222.23 M of total liabilities with total debt to equity ratio (D/E) of 44.9, which implies that NantHealth may not be able to produce enough cash to satisfy its debt commitments. NantHealth is OVERVALUED at 3.64 per share with modest projections ahead.

We determine the current worth of NantHealth using both absolute as well as relative valuation methodologies to arrive at its intrinsic value. In general, an absolute valuation paradigm, as applied to this company, attempts to find the value of NantHealth based exclusively on its fundamental and basic technical indicators. By analyzing NantHealth's financials, quarterly and monthly indicators, and related drivers such as dividends, operating cash flow, and various types of growth rates, we attempt to find the most accurate representation of NantHealth's intrinsic value. In some cases, mostly for established, large-cap companies, we also incorporate more traditional valuation methods such as dividend discount, discounted cash flow, or asset-based models. As compared to an absolute model, our relative valuation model uses a comparative analysis of NantHealth. We calculate exposure to NantHealth's market risk, different technical and fundamental indicators, relevant financial multiples and ratios, and then comparing them to NantHealth's related companies.

NantHealth Investment Alerts

NantHealth investment alerts and warnings help investors to get more proficient at understanding not only critical technical and fundamental signals but also the significant portfolio-centered indicators. These indicators include beta, alpha, and other risk-related measures that will help you in monitoring NantHealth performance across your portfolios.Please check all investment alerts for NantHealth

NantHealth Valuation Ratios as Compared to Competition

Our valuation model uses many indicators to compare NantHealth value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across NantHealth competition to find correlations between indicators driving the intrinsic value of NantHealth.

How NantHealth utilizes its cash?

To perform a cash flow analysis of NantHealth, investors first need to understand how to read the cash flow statement. A cash flow statement shows the amount of cash NantHealth is receiving and how much cash it distributes out in a given period. The NantHealth cash flow statement breaks down these inflows and outflows into different buckets, including operating activities, investing activities, and financing activities. NantHealth Net Cash Flow from Operations is most likely to increase significantly in the upcoming years. The last year's value of Net Cash Flow from Operations was reported at (10.08 Million)

Exercise or conversion by Ronald Louks of 10000 shares of NantHealth subject to Rule 16b-3

Legal trades by NantHealth insiders are very common, as founders, directors, or employees of any publicly traded firm often have stock or stock options. These trades are made public in the United States through the filing of Form 4 of the Securities and Exchange Commission. Below entry was recorded recently and is publicly available as an insider trade:

NantHealth insider trading alert for exercise of restricted stock units by Ronald Louks, Chief Operating Officer, on 18th of October 2020. This event was filed by Nanthealth Inc with SEC on 2018-02-07. Statement of changes in beneficial ownership - SEC Form 4 [view details]

Note, although insider trading is legal, in the United States, Canada, Australia, and Germany, for mandatory reporting purposes, corporate insiders are defined as a company's officers, directors, and any beneficial owners of more than 10% of a class of the company's equity securities.

What is the case for NantHealth Investors

The company generated the yearly revenue of 91.63 M. Annual Net Loss to common stockholders was (78.65 M) with gross profit of 62.2 M.

Margins Breakdown

NantHealth profit margins show the degree to which it makes money. Margin indicators are used not only by investors but also by creditors or NantHealth itself as indicators of financial health and management effectiveness. Please look more closely at the different varieties of NantHealth profit margins.

	Operating Margin	(55.03)
	EBITDA Margin	(0.25)
	Gross Margin	0.6
	Profit Margin	(0.71)

NantHealth Revenue Per Employee is increasing over the last 6 years. Moreover, NantHealth Earnings Before Interest Taxes and Depreciation Amortization EBITDA is nearly stable at the moment.

Over 3 percent rise for NantHealth. What does it mean for stockholders?

NantHealth current mean deviation boosts over 3.51. NantHealth exhibits above-average semi-deviation for your current time horizon. We encourage investors to investigate NantHealth individually to make sure intended market timing strategies and available technical indicagtors are consistent with their estimates about NantHealth future systematic risk.

Our Conclusion on NantHealth

While some other firms under the health information services industry are still a bit expensive, NantHealth may offer a potential longer-term growth to stockholders. With a less-than optimistic outlook for your 30 days horizon, it may be a good time to exit some or all of your NantHealth holdings as it seems the potential growth was already fully factored into the current price. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to NantHealth.

About Contributor

Achuva Shats is a Member of Macroaxs Editorial Board. Achuva writes about retail product and service companies from the perspective of a regular consumer and sophisticated investor at the same time. She is passionate about corporate ethics and equality in the workforce View Profile

This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Achuva Shats do not own shares of NantHealth. Please refer to our Terms of Use for any information regarding our disclosure principles.

Would you like to provide feedback on the content of this article?

You can get in touch with us directly or send us a quick note via email to editors@macroaxis.com

Macroaxis helps investors of all levels and skills to maximize the upside of all their holdings and minimize the risk associated with market volatility, economic swings, and company-specific events. View terms and conditions

Feedback Blog

Made with optimal in San Francisco

2021 Macroaxis LLC